Introduction
============

Among childhood cancers, epithelial carcinoma accounts for a very small proportion; among this, adenocarcinoma (AC) is extremely rare \[[@b1-crt-2019-092]\]. According to a study that analyzed the Korean childhood cancer using the Korea Central Cancer Registry in 1999-2011, similar results were shown \[[@b2-crt-2019-092]\]. A single cancer center series showed that gastric cancer (GC) accounts for 0.08% of cancers in patients \< 18 years of age \[[@b3-crt-2019-092]\]. The estimated colorectal carcinoma (CRC) incidence in the pediatric population is 0.3-1.5 per million \[[@b4-crt-2019-092],[@b5-crt-2019-092]\]. In contrast, in the adult population, the incidence of small bowel AC is 2.6 per 100,000 \[[@b6-crt-2019-092]\]; these figures imply a much lower incidence in children. In a nation-wide Israel study, childhood ovarian epithelial cancer (OC) comprises 0.33% of overall ovarian malignancy cases \[[@b7-crt-2019-092]\]. The low AC incidence in children has resulted in scarcity of studies; moreover, AC is rarely considered as a differential diagnosis in pediatric patients \[[@b8-crt-2019-092]\]. Approximately 60%-80% of CRC cases in children or adolescents are detected at advanced stages \[[@b9-crt-2019-092]\]. The clinical course of CRC and patients' characteristics are not well described, and the prognosis is known to be poor due to delayed diagnosis \[[@b10-crt-2019-092]\]. Pathologic features of AC may differ between adult and pediatric patients; however, these features have not been thoroughly identified. AC management in the pediatric population is consistent with that for adults \[[@b11-crt-2019-092]\], and has been reported in stomach, small bowel, and lung cancer studies \[[@b3-crt-2019-092],[@b12-crt-2019-092]-[@b17-crt-2019-092]\]. For CRC, there are a few reports with \> 10 patients \[[@b8-crt-2019-092],[@b10-crt-2019-092],[@b18-crt-2019-092]\], with one article reporting the clinicopathologic features of 74 CRC patients aged \< 18 years \[[@b8-crt-2019-092]\]. However, the largest number of pediatric GC patients reported in the medical literature in English was 5 \[[@b3-crt-2019-092]\], and OC alone has rarely been analyzed. Therefore, this study aimed to analyze the clinicopathologic features and prognosis of AC in Korean pediatric AC patients through a multicenter and large data research.

Materials and Methods
=====================

1. Patients and samples
-----------------------

This study, conducted amongst pediatric patients diagnosed with AC between January 1995 and December 2016 in 10 hospitals in Korea, included only patients aged \< 18 years at diagnosis. Members of the Korean Association of Pediatric Surgeons retrospectively retrieved patients' data from medical records on sex, age at diagnosis, symptom duration, and family history of cancer, underlying disease, tumor location, tumor size, tumor marker, and pathologic results including resection margin, chemotherapy, radiation therapy (RT), last follow-up date, date of death, recurrence, and mortality. In total, data from 100 patient records were retrieved from 11 centers (of 40), and data from 20 patient records were excluded (18 were aged ≥ 18 years and two lacked basic information). Finally, from 10 centers, 80 patients with pediatric GC, CRC, OC, lung cancer, small bowel cancer, and any other ACs were included. ACs of secondary neoplasm after treatment of primary cancer were also enrolled in this study. Any cancer occurring in relatives within two generations, including fathers, grandmothers, cousins, or uncles, was considered a positive family history. Symptom duration was defined as the period from initial symptom onset to diagnosis. Tumor size was defined as the longest diameter from the gross pathologic report. Resection margins were reviewed through microscopic pathologic reports and operation records. Pathologic stages were converted to American Joint Committee on Cancer 7th edition stages based on tumor invasion depth and the number of lymph nodes showing metastasis. Patients who received neoadjuvant, adjuvant, and palliative chemotherapy were included. The last follow-up was defined as the last outpatient visit. Recurrence was calculated only in patients undergoing curative intent surgery. The survival period was defined as the interval from AC diagnosis to allcause death.

Treatment was performed according to the general cancer treatment principles applied for adults. In stage 4 patients with distant metastasis, curative intent surgery was not performed. Palliative surgery was performed if necessary, and chemotherapy or RT was performed as indicated. In patients without distant metastasis, curative intent surgery was performed, and adjuvant chemotherapy or RT was added according to the pathologic results and compliance of each patient.

SPSS ver. 23.0 (IBM Corp., Armonk, NY) was used for statistical analysis. Categorical data are reported as numbers and percentages, while continuous data are reported as medians and ranges. Survival rates were calculated by the Kaplan-Meier method, and the log-rank test was used for comparing curves. p-values \< 0.05 were considered significant. Greenwood formula was used to calculate survival estimates, reported as 5-year survival rate and 95% confidence interval (CI). Missing values were excluded from the analysis.

2. Ethical statement
--------------------

The institutional review board of Seoul National University Hospital approved the study (1808-129-967), and owing to its retrospective nature, informed consents were waived. All methods used in this study complied with the relevant guidelines and regulations.

Results
=======

1. Demographic characteristics
------------------------------

[Table 1](#t1-crt-2019-092){ref-type="table"} shows the clinical characteristics of all patients. The number of occurrences of GC, CRC, OC, lung cancer, and small bowel cancer was 15, 32, 18, 4, and 1, respectively. The origin of other cancers included head and neck, bile duct, pancreas, uterine cervix, and urinary bladder. AC of unknown origin was also included in the "other" category. Ten patients had cancer at other sites, while head and neck cancer was found in three. There was one occurrence each of cholangiocarcinoma, pancreas, cervix, and bladder cancers, as well as three unknown origin cancers in the brain, spine, and bone marrow, where AC is not normally found. Detailed sites of other cancers are shown in [Table 2](#t2-crt-2019-092){ref-type="table"}. Of the 80 patients, 37 (46.3%) were male, and the proportion increased to 59.7% when the 18 OC patients were excluded. The median age was 15 years (range, 10 to 17 years). As age increased, the number of patients tended to increase, with 19, 28, and 33 cases aged 10-13, 14-15, and 16-17 years, respectively. The median symptom duration was 1.8 months (range, 0.2 to 34.4 months). The number of patients with stages 1-4 cancer was 27, 8, 12, and 30, respectively. Forty-nine patients (61.3%) underwent chemotherapy and 10 (12.5%) underwent RT. The median follow-up period was 2.0 years (range, 0 to 20.4 years).

2. Diagnosis-based clinicopathologic characteristics
----------------------------------------------------

[Table 3](#t3-crt-2019-092){ref-type="table"} shows the clinicopathologic characteristics according to diagnosis. The number of patients with a positive family history was six (40.0%) for GC, eight (25.0%) for CRC, one (25.0%) for lung cancer, and one (10.0%) for other cancers. Seven CRC patients had underlying disease; three had familial adenomatous polyposis (FAP), and one each had ulcerative colitis, juvenile polyposis (JP), neurofibromatosis type 1 (NF-1), and Louis-Bar syndrome. One patient each with GC, lung cancer, small bowel cancer, and cholangiocarcinoma had underlying disease. Median symptom duration ranged between 1.0 and 2.4 months. Abdominal pain was the most common symptom in GC and CRC (60.0% in GC, 62.5% in CRC). The most common feature of OC was abdominal distension (72.2%). Most masses in GC (53.3%, 8/15) were located in the gastric body. Detailed locations of each cancer are shown in [Table 2](#t2-crt-2019-092){ref-type="table"}. Tumor size was the largest in ovarian cancer (median, 20 cm; range, 12.0 to 40.0 cm). R0 resection was achieved in all OC patients. Less than 50% of patients achieved R0 resection in GC and CRC (46.7% in GC, 40.6% in CRC). Of GC patients, 83.3% (10/12) were poorly differentiated (PD), compared to 33.3% (8/24) of CRC patients. Overall, 52.2% (12/23) CRC patients and 7.1% (1/14) OC patients were positive for lymphovascular invasion. Nine OC patients were negative for perineural invasion, but 50% (7/14) of CRC patients were positive. Less than 10% of patients with CRC had stage 1 disease (9.4%); 20% and 94.4% of GC and OC were stage 1,respectively. As shown in [Table 4](#t4-crt-2019-092){ref-type="table"}, seven GC patients received chemotherapy (in the adjuvant setting for four patients and palliative setting for 3), while 4 CRC patients underwent RT. Irradiation sites included the head, spine, brain, and abdominal cavity ([Table 4](#t4-crt-2019-092){ref-type="table"}).

3. Tumor markers and pathology
------------------------------

Two tumor markers (carcinoembryonic antigen \[CEA\] and cancer antigen 19-9 \[CA 19-9\]), were investigated. CEA and CA 19-9 results were available for nine and eight GC patients, respectively. The median CEA and CA 19-9 values were 1.4 ng/mL (range, 0.1 to 52.1 ng/mL) and 8.1 U/mL (range, 1.9 to 106.0 U/mL), respectively. The results for other cancers are shown in [Table 5](#t5-crt-2019-092){ref-type="table"}.

Furthermore, 35.7% of GC (5/14) and 17.4% of CRC (4/23) patients exhibited poorly cohesive carcinoma. Regarding CRC, 30.4% were mucinous AC, and 94.4% of the OC cases (17/18) were mucinous cystadenocarcinoma ([Table 6](#t6-crt-2019-092){ref-type="table"}). Of the 32 CRC patients, 22 were available for lymph node retrieval and had data concerning lymph node metastasis. The median number of retrieved lymph nodes and metastatic lymph nodes was 31 (range, 1 to 138) and 2 (range, 0 to 24), respectively. The results for other cancers are shown in [Table 6](#t6-crt-2019-092){ref-type="table"}.

4. Survivals and prognostic factors
-----------------------------------

The 5-year overall survival estimate was 57.9%±11.5% for all patients ([Fig. 1A](#f1-crt-2019-092){ref-type="fig"}), and 58.2%±25.7%, 41.5%±18.2%, 87.5%± 16.2%, and 64.0%±34.4% for GC, CRC, OC, and other cancers, respectively ([Fig. 1B](#f1-crt-2019-092){ref-type="fig"}). The 5-year survival rate following R0 resection was 88.7%. All three patients with R1 resection survived, and one patient with R2 resection died after 8 months of diagnosis. None of the patients with palliative operation or inoperable status was long-term survivor ([Fig. 1C](#f1-crt-2019-092){ref-type="fig"}). The 5-year survival rate for stages 1 and 3 were 96% and 56.3%, respectively. All seven patients with stage 2 cancer were alive at the last follow-up. The longest survival for patients with stage 4 disease was 3.4 years and the 5-year survival rate was 8.4% ([Fig. 1D](#f1-crt-2019-092){ref-type="fig"}). The 5-year survival rate was 97.0%±3.0% and 21.0%±7.6% for stage 1 or 2 and 3 or 4 (p \< 0.001). GC, CRC, small bowel cancer, pancreatic cancer, and cholangiocarcinoma were grouped as gastrointestinal (GI) cancer while other cancers (ovary, lung, and unknown origin tumor) were grouped as non-GI cancer. The overall survival differed significantly between the two groups (5-year survival GI, 44.7%; non-GI, 78.8%; p=0.007) ([Fig. 2](#f2-crt-2019-092){ref-type="fig"}). The survival rate was calculated to examine the prognostic value of CEA in 45 patients. The 5-year survival rate in patients with CEA levels \< 3 and \> 3 ng/mL was 69.3% and 23.8%, respectively ([Fig. 3](#f3-crt-2019-092){ref-type="fig"}). The effects of GI cancer and CEA level were adjusted in the multivariable analysis. CEA level was the only factor influencing survival (hazard ratio, 3.587; 95% CI, 1.347 to 9.552; p=0.01) ([S1 Table, Supplementary Materials](#SD1-crt-2019-092){ref-type="supplementary-material"}).

5. Subgroup analysis
--------------------

The effects of underlying disease on the stage were analyzed in CRC patients. There was no statistical difference in stage distribution between the patients with and without underlying disease ([S2 Table, Supplementary Materials](#SD2-crt-2019-092){ref-type="supplementary-material"}). Advanced stage patients were analyzed for differences in survival rates depending on whether chemotherapy was performed or not. Survivals were not significantly different in the patients with and without chemotherapy (5-year survival rates 18.8% and 24.2% respectively, p=0.263) ([S3 Fig., Supplementary Materials](#SD3-crt-2019-092){ref-type="supplementary-material"}).

Discussion
==========

This study was a clinical series of AC, an extremely rare disease entity, including relatively large GC and OC, in children and adolescents. Despite its rarity, it is evident that a variety of ACs occurred in children and adolescents. The specific tumor locations were the stomach, colon and rectum, ovary, lung, small bowel, oral cavity, nasal cavity, parotid gland, pancreatic duct, urinary bladder, and uterine cervix. Cancer of unknown origin was also identified. Regardless of the cancer type, the ages at diagnosis were similar. Almost half of all patients (n=33) had a \> 2-month delay from initial symptom onset to diagnosis. Approximately 40% of GC and CRC patients had a positive family history. About half of the GC and CRC patients were diagnosed with distant metastasis. OC tumor size was relatively large, but most cases presented at an early stage. Regardless of the family history of AC, diagnosis of pediatric AC was relatively delayed, with a tendency of diagnosis at an advanced stage.

GI tumors comprised \< 5% of all malignancies in children. Of these, less than 0.05% were primary gastric carcinoma \[[@b19-crt-2019-092]\]. Among 15 patients in our study, six (40%) had a family history of cancer, among whom, three had relatives who died of GC. Median symptom duration was 1 month in GC. Maconi et al. \[[@b20-crt-2019-092]\] reported a mean symptom duration of 16.8 weeks with alarming symptoms and 29.3 weeks with no alarming symptoms in GC patients aged \< 45 years. These results are comparable to ours, although several bias may exist in the comparison between the previous study and ours. For example, because patients in our study were children or adolescents; they could neither remember the exact time of initial symptoms, nor the necessity of going to the hospital. It is known that cancer is usually found at a later stage in children compared to adults \[[@b21-crt-2019-092]\]. To compare the pediatric GC survivals between our study and previous ones, 36 patients in 22 case reports or series were identified, and the 5-year survival rate was found to be 8.4% ([S4 Fig., Supplementary Materials](#SD4-crt-2019-092){ref-type="supplementary-material"}). Due to the heterogeneity of the included studies and the evolution of treatment during the studies, it is difficult to directly compare the survival rates in these studies and ours. Except two patients who showed general weakness and weight loss, the majority of symptoms were nonspecific, such as abdominal pain, indigestion, or vomiting. Hence, if symptoms persist for a long time, although they may appear negligible, thorough examinations may be necessary.

GI cancer is the most frequent form of hereditary neoplasia, and approximately 10%-20% of CRCs in children and adolescents occur in those with familial history \[[@b11-crt-2019-092],[@b22-crt-2019-092]\]. In our study, eight CRC patients (25%) had a family history of cancer, and this is well correlated with values from other studies. Overall, 3%-5% of the population had specific underlying predisposing conditions, including inflammatory bowel disease, Peutz-Jeghers syndrome, JP, hereditary mixed polyposis syndrome, hereditary non-polyposis colon cancer (HNPCC), and FAP \[[@b5-crt-2019-092],[@b13-crt-2019-092]\]. Among these, HNPCC is associated with the highest risk \[[@b5-crt-2019-092]\]. In our study, seven (21.9%) patients had underlying disease, a proportion that is higher than that previously reported. Not only well-known underlying disease, but also NF-1 and Louis-Bar syndrome were included. Zoller et al. \[[@b23-crt-2019-092]\] reported four CRCs in 70 NF-1 patients during 11-year follow-up. There was one published pediatric AC case with NF-1 \[[@b24-crt-2019-092]\]. One CRC patient in this study who had Louis-Bar syndrome, also called ataxia-telangiectasia, was previously reported \[[@b25-crt-2019-092]\]. Non-Hodgkin lymphoma and solid tumors can occur, but CRC is a rare cancer in ataxia-telangiectasia.

Decreased appetite and weight loss, changes in bowel habits, and rectal bleeding with changes in stool caliber may be observed in CRC patients \[[@b13-crt-2019-092]\]. In our study, nonspecific symptoms were common, but hematochezia and weight loss accounted for 28.1% of symptoms. Some authors reported a symptom duration of \> 10 weeks in adult CRC \[[@b26-crt-2019-092],[@b27-crt-2019-092]\]; this appears to be shorter than that in pediatric CRC in this study. Most CRCs in adults are moderately differentiated (MD) or well differentiated (WD) ACs. In contrast, more than half of reported childhood CRC cases are PD mucinous ACs, many of which are of the signet-ring cell type \[[@b13-crt-2019-092]\]. In our study, there were five WD, 11 MD, and eight PD cases. Mucinous type accounted for 21.9% and poorly cohesive cancer for 12.5%. Long-term survival rates in pediatric CRC patients were 20%-50% in other studies \[[@b4-crt-2019-092],[@b9-crt-2019-092],[@b11-crt-2019-092]\], and 41.5% in ours. Sultan et al. \[[@b28-crt-2019-092]\] reported only on 159 children/adolescent CRC patients through the Surveillance, Epidemiology, and End Results database from 1973 to 2005. They also confirmed the poor prognostic features of pediatric CRC (i.e., mucinous AC and signet ring cell carcinoma). The 5-year survival estimate in that study (40%±4.2%), was comparable with our result (41.5%±18.2%). This low survival rate of CRC seems to be associated with the pathologic feature of poor differentiation.

Epithelial neoplasms are the most frequent histological type in adult OCs, while in childhood and adolescence, the majorities are non-epithelial and of germ cell origin \[[@b7-crt-2019-092],[@b29-crt-2019-092]\]. In our study, 17 cases were of mucinous type and one was of the serous type.

One female patient with lung cancer in this study was treated for papillary thyroid cancer prior to the diagnosis of lung cancer. Three years before she was diagnosed with lung cancer, she received a cumulative of 350 mCi radioactive iodine ablation in a year. Teng et al. \[[@b30-crt-2019-092]\] reported that the risk of secondary cancer increases when the cumulative radiation exceeds 150 mCi, and a 2.14-fold increase is noted in female lung cancer patients. Rojas et al. \[[@b31-crt-2019-092]\] reported on 211 children with malignant pulmonary tumors using the National Cancer Database. Of these, 16 ACs were identified, and their 5-year survival rate was 26%. Childhood pulmonary AC is so rare in Korea, that only few case reports have been published so far \[[@b15-crt-2019-092]\].

Yoon et al. \[[@b32-crt-2019-092]\] reported the occurrence of cholangiocarcinoma in a patient who previously underwent Kasai operation (owing to biliary atresia). Cholangiocarcinoma arising in biliary atresia patients with non-surgical treatment was also reported \[[@b33-crt-2019-092]\].

Since little is known about the treatment for pediatric AC, the treatment principles follows those in adult AC according to previously reported articles \[[@b3-crt-2019-092],[@b8-crt-2019-092]\]. Hill et al. \[[@b8-crt-2019-092]\], in a review on pediatric CRC, reported chemotherapy and RT. Subbiah et al. \[[@b3-crt-2019-092]\] reported the use of platinum-based agent and 5-fluorouracil in pediatric GC and bevacizumab was used in one patient. In the present study, 5-fluorouracil and platinumbased agent were used as the first line chemotherapy in CRC. There were also cases where bevacizumab was added. However, there was no benefit with the chemotherapy, and this was thought to be due to the large number of patients with advanced stage.

The usefulness of CEA for prognosis in pediatric AC has rarely been investigated. One study investigated the role of CEA in detecting recurrence after surgery for CRC, in 11 pediatric patients \[[@b34-crt-2019-092]\]. Sensitivity and specificity for recurrence detection in CRC was 64% and 77%, respectively. This result suggests the value of CEA as an independent prognostic factor, but this requires more prospective studies.

This study has several limitations. Although this was a multicenter study, we did not include all pediatric AC cases in the country during the study period, mainly because the only institutions with pediatric surgery participated in this study. Thus, it was not possible to determine the national AC incidence. Comparison with adult AC was impossible due to the study design and the lack of pediatric AC results. Survival analysis based on examined factors was not performed. During 20 years of enrollment, the staging system had changed, and treatment modality had greatly evolved; thus, the data may not truly reflect this change. Further, the biggest limitation may be the lack of molecular studies, underlying genetic pathogenesis, and the use of the latest tumor markers. However, despite these limitations, the analysis of many clinical features of pediatric ACs, including several GC cases, makes our study findings valuable.

ACs in pediatric patients arise from various organs and are often diagnosed at advanced stages because of its rarity or the characteristics of children. Family history of cancer or underlying disease relevant to malignancy was positive for 30%. Overall 5-year survival rate for all ACs was 57.9%. ACs that originated from GI and CEA level \>3 ng/mL at diagnosis are poor prognosis factors for pediatric ACs. Because AC is extremely rare in pediatric population, more large prospective multicenter studies on the treatment and prognosis are warranted for further understanding and better survival of this malignancy.
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###### 

Multivariable analysis of the effects of the CEA level and GI cancer

###### 

Stage distribution in CRC patients according to underlying disease

###### 

Survival curves of the patients with stage 3 or 4 disease according to chemotherapy (p=0.263).

###### 

Survival curve of 36 gastric cancer (GC) patients aged \< 20 years based on previously reported cases (1960-2018). The 5-year survival rate was 8.4%.

![(A) Survival distribution of all 80 patients. The 5-year overall survival rate was 57.9%. (B) Survival distribution according to the diagnosis. (C) Survival distribution according to the resection type. (D) Survival distribution according to the stage. The number of survival periods represents the year for each figure.](crt-2019-092f1){#f1-crt-2019-092}

![Comparison of overall survival between the groups with gastrointestinal cancer (GI) and without GI (non-GI). The number of survival periods represents the year. GI, gastrointestinal cancers (gastric cancer, colorectal cancer, small bowel cancer, pancreatic cancer, cholangiocarcinoma); Non-GI, all cancers except for the abovementioned cancers.](crt-2019-092f2){#f2-crt-2019-092}

![Comparison of survival in patients with carcinoembryonic antigen (CEA) level \< 3 ng/mL and \> 3 ng/mL. The value for the survival period represents the year.](crt-2019-092f3){#f3-crt-2019-092}

###### 

Clinical characteristics of all patients

                                             No. (%) (n=80)
  ------------------------------------------ ----------------
  **Location**                               
   Stomach                                   15 (18.8)
   Colon                                     32 (40.0)
   Ovary                                     18 (22.5)
   Lung                                      4 (5.0)
   Small bowel                               1 (1.3)
   Others                                    10 (12.5)
    Head and neck                            3
    Unknown origin                           3
    Bile duct                                1
    Pancreas                                 1
    Cervix                                   1
    Urinary bladder                          1
  **Male sex**                               37 (46.3)
  **Age, median (range, yr)**                15 (10-17)
   10-13                                     19
   14-15                                     28
   16-17                                     33
  **Symptom duration, median (range, mo)**   1.8 (0.2-34.4)
   \< 2                                      36
   \> 2                                      33
  **Stage**                                  
   1                                         27 (35.1)
   2                                         8 (10.4)
   3                                         12 (15.6)
   4                                         30 (39.0)
  **Operation**                              
   R0                                        46 (59.7)
   R1                                        3 (3.9)
   R2                                        1 (1.3)
   Palliative                                16 (20.8)
   Not done                                  11 (14.3)
  **Chemotherapy**                           49 (61.3)
  **Radiation therapy**                      10 (12.5)
  **Follow-up period, median (range, yr)**   2.0 (0-20.4)
  **Recurrence**                             11 (22.0)
  **5-Year survival rate (%)**               57.9

###### 

Detailed locations and symptoms of each type of cancer

                                                            Stomach (n=15)     Colon (n=32)           Ovarian (n=18)            Lung (n=4)        Small bowel (n=1)   Others^[a)](#tfn1-crt-2019-092){ref-type="table-fn"}^
  --------------------------------------------------------- ------------------ ---------------------- ------------------------- ----------------- ------------------- -------------------------------------------------------
  Location                                                  8 Body             7 Rt.                  11 Rt.                    2 Rt.             1 Jejunum           1 Nasal cavity
                                                            3 Antrum           4 Trans                7 Lt.                     1 Lt                                  1 Oral cavity
                                                            4 Multiple         5 Lt.                                                                                  1 Parotid gland
                                                            4 LC               8 Sigmoid                                                                              1 Pancreas tail
                                                            7 GC               3 Rectum                                                                               1 Bone marrow
                                                            2 Encircle         3 Multiple                                                                             1 Spine
                                                                                                                                                                      1 Brain
                                                                                                                                                                      1 Uterine cervix
                                                                                                                                                                      1 Urinary bladder
                                                                                                                                                                      1 Bile duct, B8
  Symptoms^[b)](#tfn2-crt-2019-092){ref-type="table-fn"}^   9 Abdominal pain   20 Abdominal pain      13 Abdominal distension   1 Cough           1 Abdominal pain    Nasal obstruction
                                                            4 Indigestion      7 Hematochezia         2 Abdominal pain          1 Hemoptysis      1 Weight loss       Incidental mass
                                                            2 Vomiting         7 Bowel habit change   2 Dyspnea                 1 Weight loss                         Infra-auricular pain
                                                            1 Distension       3 Vomiting             1 Weight loss             1 Multiple pain                       Vomiting
                                                            1 Weight loss      3 Distension           1 Bowel habit change                                            Bruising
                                                            1 Weakness         2 Weight loss                                                                          Neck pain
                                                                               1 Dyspepsia                                                                            Seizure
                                                                                                                                                                      Vaginal bleeding
                                                                                                                                                                      Hematuria

LC, lesser curvature; GC, greater curvature; Rt., right; Lt., left.

Each symptom corresponds to the cancer given in the same column in the same order,

Some patients had many symptoms; all symptoms were counted.

###### 

Clinicopathologic characteristics of individual types of cancer

                                 Stomach (n=15)                      Colon (n=32)     Ovarian (n=18)     Lung (n=4)      Small bowel (n=1)   Others (n=10)
  ------------------------------ ----------------------------------- ---------------- ------------------ --------------- ------------------- ----------------
  **Male sex**                   7 (46.7)                            22 (68.8)        \-                 3 (75.0)        1 (100)             4 (40.0)
  **Age (yr)**                   16 (12-17)                          15 (11-17)       15 (10-17)         15.5 (13-17)    12                  14 (10-17)
  **Family history of cancer**   6 (40.0)                            8 (25.0)         0                  1 (25.0)        0                   1 (10.0)
  **PMHx**                       1 (6.7)                             7 (21.9)         \-                 1 (25.0)        1 (100)             1 (10.0)
                                 1 HLH with autoimmune enteropathy   UC 1                                1 PTC           1 PJS               1 BA in CC
                                                                     1 JP                                                                    
                                                                     1 NF-1                                                                  
                                                                     1 LBS                                                                   
                                                                     3 FAP                                                                   
  **Symptom duration (mo)**      1.0 (0.2-24.4)                      1.9 (0.3-29.4)   1.9 (0.7-34.4)     2.4 (1.8-2.9)   2.0                 2.2 (0.7-24.5)
  **Size (cm)**                  4.0 (0.0-8.0)                       5.0 (0.7-17.0)   20.0 (12.0-40.0)   6.5 (0.6-6.7)   14.5                3.0 (0.5-5.0)
  **Operation**                                                                                                                              
   R0                            7                                   13               18                 2               1                   5
   R1                            0                                   0                0                  0               0                   3
   R2                            0                                   1                0                  0               0                   0
   Palliative                    2                                   12               0                  1               0                   1
   No                            6                                   5                0                  0               0                   0
  **Differentiation**                                                                                                                        
   WD                            0                                   5                7                  0               1                   0
   MD                            2                                   11               4                  0               0                   1
   PD                            10                                  8                0                  1               0                   1
  **Lymphovascular invasion**                                                                                                                
   Yes                           1                                   12               1                  0               0                   0
   No                            3                                   11               13                 1               1                   3
  **Perineural invasion**                                                                                                                    
   Yes                           3                                   7                0                  0               \-                  2
   No                            1                                   7                9                  1               \-                  2
  **Stage**                                                                                                                                  
   1                             3                                   3                17                 1               0                   3
   2                             1                                   5                0                  0               1                   1
   3                             3                                   7                1                  1               0                   0
   4                             8                                   16               0                  1               0                   5
  **Chemotherapy**               7 (46.7)                            24 (75.0)        13 (72.2)          2 (50.0)        1 (100)             2 (20.0)
  **Radiation therapy**          0                                   4 (12.5)         1 (5.6)            1 (25.0)        0                   4 (40.0)
  **Recurrence**                 2 (28.6)                            3 (21.4)         4 (22.2)           0               1 (100)             1 (12.5)
  **5-Year survival rate (%)**   58.2                                41.5             87.5               \-              \-                  64.0

Values are presented as number (%) or median (range). PMHx, past medical history; HLH, hemophagocytic lymphohistiocytosis; FAP, familial adenomatous polyposis; UC, ulcerative colitis; JP, juvenile polyposis; NF-1, neurofibromatosis type 1; LBS, Louis-Bar syndrome; FAP, familial adenomatous polyposis; PTC, papillary thyroid cancer; PJS, Peutz-Jeghers syndrome; BA, biliary atresia; CC, cholangiocarcinoma; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated.

###### 

Chemotherapy and radiation therapy

                          Stomach (n=15)   Colon (n=32)   Ovarian (n=18)   Lung (n=4)                    Small bowel (n=1)   Others (n=10)
  ----------------------- ---------------- -------------- ---------------- ----------------------------- ------------------- ----------------------------------------------------------
  **Chemotherapy**        7                24             13               2                             1                   2
   Neoadjuvant            0                1              1                0                             0                   0
   Adjuvant               4                12             13               2                             1                   1
   Palliative             3                13             0                0                             0                   1
  **Detailed regimen**    FP               FOLFOX         T-CDDP           \-                            \-                  Cisplatin^[a)](#tfn3-crt-2019-092){ref-type="table-fn"}^
                          DP               FOLFIRI        CDDP                                                               
                          Doxifluridine    XELOX                                                                             
                                           FL                                                                                
  **Radiation therapy**   \-               4              1                1                             \-                  4
   Location, dose                          Head           Pelvis, 20 Gy    Left femur and spine, 60 Gy                       Brain, 30 Gy
                                           Spine                                                                             Spine, 45 Gy
                                           Brain, 18Gy                                                                       Pelvis, 50 Gy
                                           Abdomen                                                                           Abdomen, 65 Gy

FP, 5-fluorouracil and cisplatin; DP, docetaxcel and cisplatin; FOLFOX, folinic acid, fluorouracil and oxaliplatin; FOLFIRI, folinic acid, fluorouracil and irinotecan; XELOX, capecitabine and oxaliplatin; FL, 5-fluorouracil and leucovorin; T-CDDP, paclitaxel and cisplatin; CDDP, cisplatin.

Cisplatin: unknown origin.

###### 

Tumor markers according to the cancer diagnosis

  Tumor marker             Stomach (n=15)    Colon (n=32)        Ovarian (n=18)     Lung (n=4)   Small bowel (n=1)   Others (n=10)
  ------------------------ ----------------- ------------------- ------------------ ------------ ------------------- -----------------
  **CEA**                                                                                                            
   Available               9                 23                  10                 1            1                   1
   Median (range, ng/mL)   1.4 (0.1-52.1)    5.2 (0.1-15,190)    0.95 (0.2-18.9)    1            0.3                 1.1
  **CA 19-9**                                                                                                        
   Available               8                 10                  11                 0            1                   2
   Median (range, U/mL)    8.1 (1.9-106.0)   74.2 (11.3-1,980)   5.0 (0.1-16,050)   \-           4.6                 17.9 (4.6-31.2)

CEA, carcinoembryonic antigen; CA 19-9, cancer antigen 19-9.

###### 

Histologic type and lymph node status

                                                              Stomach (n=15)   Colon (n=32)   Ovarian (n=18)   Lung (n=4)   Small bowel (n=1)   Others (n=10)
  ----------------------------------------------------------- ---------------- -------------- ---------------- ------------ ------------------- ---------------
  **Histology**                                               14               23             18               3            1                   10
   Adenocarcinoma                                             8                11             \-               2            1                   6
   Tubular                                                    1                \-             \-               \-           \-                  \-
   Papillary                                                  \-               1              \-               \-           \-                  \-
   Mucinous                                                   \-               7              17               \-           \-                  2
   Serous                                                     \-               \-             1                \-           \-                  \-
   PCC                                                        5                4              \-               \-           \-                  \-
   Others                                                     \-               \-             \-               1            \-                  2
  **Lymph node status**                                       6                22             7                1            1                   4
   Retrieval^[a)](#tfn4-crt-2019-092){ref-type="table-fn"}^   39.5 (22-48)     31 (1-138)     16 (4-29)        10           3                   9.5 (4-10)
   Positive                                                   3.5 (0-9)        2 (0-24)       0 (0-0)          4            0                   0 (0-4)

Values are presented as number or median (range). PCC, poorly cohesive carcinoma.

Under 12 lymph node retrievals occurred in 2, 1, and 8 patients of stomach, colon, and ovary cancer, respectively.

[^1]: Hee-Beom Yang and Jung-Man Namgoong contributed equally to this work.
